Metformin is still today the first-line therapy, has been successfully used for more than 50 years and is the most widely used drug to treat type II Diabetes. It is derived from a plant called Gallega officinalis and is believed to be useful against a number of other diseases other than Diabetes. It has also been associated with a reduced risk of developing cancer and a better overall survival rate.

It triggers skeletal muscle cells to raise their glucose intake through a not fully understood mechanism. In alternative oncology, Metformin seems to activate cellular autophagy (the natural process in which cells “eat” old proteins or other structures to repurpose them) and inhibit the mTOR signaling pathway in the immune system. The autophagy is an important mechanism to prevent cancer cells for developing and the mTOR pathway is believed to be key for anti-cancer treatment.

Due to its capability of avoiding cancer cell development and its inhibition of the mTOR pathway (which is shared by many different cancer types), Metformin can be used against most types of cancer. It is also used outside of alternative oncology as the standard treatment for Diabetes Type II, polycystic ovaries and metabolic syndrome.

We strongly recommend the use of Metformin by cancer patients. It is a vital part of a more comprehensive program and must always be taken under the supervision of a physician. It is an oral drug that is usually well-tolerated and has a good safety profile. Patients can sometimes experience some diarrhea and stomach aches. Patients with severe kidney and liver impairment may not use this drug.